Advertisement

The internationalization of innovation towards the South: A historical case study of a global pharmaceutical corporation in China (1993–2017)

  • Shasha Zhao
  • Hui Tan
  • Marina Papanastassiou
  • Anne-Wil Harzing
Article

Abstract

Intensified competition means that multinational enterprises (MNEs) are increasingly concerned with locating innovation activities in the most appropriate locations. This had led to emerging economies in the South becoming an important destination of R&D-related foreign direct investment (FDI), departing from their traditional role as low-cost production sites. Thus far, however, our understanding of this transformation process is limited. The purpose of this article is therefore to explore the process by which foreign MNEs’ low-value-adding operations in the South are transformed into high-value-adding R&D operations. Drawing on the current literature, we construct a framework of evolution consisting of four major waves of R&D internationalization and corresponding R&D objectives. To better understand how these waves have evolved over time, we focus on the South and trace the process of change using a single historical case study: AstraZeneca in China between 1993 and 2017. We find evidence of idiosyncratic location-bound conditions offering both opportunities and resources. The gradual development of these favourable conditions, along with AstraZeneca’s deepening local knowledge, triggered a transformation process in their operations in China. Our study thus offers important historical insights, which present a platform for future research providing more nuanced theoretical explanations of the four waves of R&D internationalization.

Keywords

R&D internationalization Emerging economies North and south Historical case study 

Notes

Acknowledgements

We are thankful for the useful comments and suggestions given by Ram Mudambi, Emmanuella Plakoyiannaki, and participants of the Academy of International Business Conference on earlier versions of the paper. We are also grateful for the constructive comments offered by the editor and reviewers, which have helped to enhance the clarity of the arguments in our paper considerably.

References

  1. Abbott, A. 2001. Time matters: On theory and method. Chicago: University of Chicago Press.Google Scholar
  2. Almeida, P., & Kogut, B. 1999. Localization of knowledge and the mobility of engineers in regional networks. Management Science, 45(7): 905–917.CrossRefGoogle Scholar
  3. Altenburg, T., Schmitz, H., & Stamm, A. 2008. Breakthrough China’s and India’s transition from production to innovation. World Development, 36(2): 325–344.CrossRefGoogle Scholar
  4. Archibugi, D., & Iammarino, S. 2002. The globalization of technological innovation: Definition and evidence. Review of International Political Economy, 9(1): 98–122.CrossRefGoogle Scholar
  5. Asakawa, K., & Ashok, S. 2008. Internationalization of R&D in China and India: Conventional wisdom versus reality. Asia Pacific Journal of Management, 25(3): 375–394.CrossRefGoogle Scholar
  6. Asiabiotech News. 2007. AstraZeneca enhances clinical research capabilities in China with First Clinical Pharmacology Unit. Asiabiotech News.Google Scholar
  7. AstraZeneca PLC. 2001. Annual report. Cambridge: AstraZeneca PLC.Google Scholar
  8. AstraZeneca PLC. 2002. Annual report. Cambridge: AstraZeneca PLC.Google Scholar
  9. AstraZeneca PLC. 2006. Annual report. Cambridge: AstraZeneca PLC.Google Scholar
  10. AstraZeneca PLC. 2008. Annual report. Cambridge: AstraZeneca PLC.Google Scholar
  11. AstraZeneca PLC. 2009. Annual report. Cambridge: AstraZeneca PLC.Google Scholar
  12. AstraZeneca PLC. 2010. Annual report. Cambridge: AstraZeneca PLC.Google Scholar
  13. AstraZeneca PLC. 2016. Annual report. Cambridge: AstraZeneca PLC.Google Scholar
  14. Athreye, S., Tuncay-Celikel, A., & Ujjual, V. 2014. Internationalisation of R&D into emerging markets: Fiat’s R&D in Brazil, Turkey and India. Long Range Planning, 47(1–2): 100–114.CrossRefGoogle Scholar
  15. Athreye, S., Batsakis, G., & Singh, S. 2016. Local, global, and internal knowledge sourcing: The trilemma of foreign-based R&D subsidiaries. Journal of Business Research, 69(12): 5694–5702.CrossRefGoogle Scholar
  16. Awate, S., Larsen, M. M., & Mudambi, R. 2015. Accessing vs sourcing knowledge: A comparative study of R&D internationalization between emerging and advanced economy firms. Journal of International Business Studies, 46(1): 63–86.CrossRefGoogle Scholar
  17. Bartlett C. A., & Beamish, P. W. 2013. Transnational management: Text, cases & readings in cross-border management, 7th ed. Burr Ridge: McGraw-Hill/Irwin.Google Scholar
  18. Bas, C. L., & Sierra, C. 2002. Location versus home country advantages in R&D activities: Some further results on multinationals’ locational strategies. Research Policy, 31(4): 589–609.CrossRefGoogle Scholar
  19. Behrman, J. N., & Fischer, W. A. 1980. Overseas R&D activities of transnational companies. International Executive, 22(3): 15–17.CrossRefGoogle Scholar
  20. Bernstein Research. 2009. Black book—Global pharmaceuticals: Emerging markets should infuse badly needed revenues for years to come: 99–104. New York: Bernstein Global Wealth Management.Google Scholar
  21. Biopharmadive News. 2018. AstraZeneca pins its hopes on China. Biopharmadive News: February 2Google Scholar
  22. Brash, D. T. 1966. American investment in Australian industry. Canberra: Australian National University Press.Google Scholar
  23. Bresciani, S., & Ferraris, A. 2016. Innovation-receiving subsidiaries and dual embeddedness: Impact on business performance. Baltic Journal of Management, 11(1): 108–130.CrossRefGoogle Scholar
  24. Bruche, G. 2009. The emergence of China and India as new competitors in MNCs’ innovation networks. Competition & Change, 13(3): 267–288.CrossRefGoogle Scholar
  25. Cantwell, J. 1992. The internationalization of technological activity and its implication for competitiveness. In O. Grandstrand, A. Hakanson, & S. Sjolander (Eds.). Technology management and international business: Internationalization of R&D and technology. Chichester: John Wiley & Sons.Google Scholar
  26. Cantwell, J., & Iammarino, S. 1998. MNCs, technological innovation and regional systems in the EU: Some evidence in the Italian case. International Journal of Economics of Business, 5(3): 383–408.CrossRefGoogle Scholar
  27. Cantwell, J., & Janne, O. 1999. Technological globalization and innovative centres: The role of corporate technological leadership and locational hierarchy. Research Policy, 28(2/3): 119–144.CrossRefGoogle Scholar
  28. Cantwell, J., Dunning, J. H., & Lundan, S. M. 2010. An evolutionary approach to understanding international business activity: The co-evolution of MNEs and the institutional environment. Journal of International Business Studies, 41(4): 567–586.CrossRefGoogle Scholar
  29. Castellani, D., & Zanfei, A. 2006. Multinational firms, innovation and productivity. London: Edward Elgar.Google Scholar
  30. Castellani, D., Jimenez, A., & Zanfei, A. 2013. How remote are r&d labs? Distance factors and international innovative activities. Journal of International Business Studies, 44(7): 649–675.CrossRefGoogle Scholar
  31. Chemical Market Reporter 2001. AstraZeneca. Opens Plant in China, 259(19): 14–15.Google Scholar
  32. Chen, S. H. 2004. Taiwanese IT firms’ offshore R&D in China and the connection with the global innovation network. Research Policy, 33(2): 337–349.CrossRefGoogle Scholar
  33. Child, J., Rodrigues, S. B., & Tse, K. K. T. 2012. The dynamics of influence in corporate co-evolution. Journal of Management Studies, 49(7): 1246–1273.CrossRefGoogle Scholar
  34. Chi-Med. 2017. Chi-Med and AstraZeneca initiate SAVOIR, a global phase III trial of Savolitinib in papillary renal cell carcinoma. Chi-Med News: June 29.Google Scholar
  35. China Daily News. 2018. Innovation at the heart of development. China Daily News: May 24.Google Scholar
  36. China Food & Drug Administration. n.d. Domestic and imported drug database. Beijing: China Food and Drug Administration.Google Scholar
  37. China Ministry of Science and Technology. n.d. S&T programs. Beijing: Ministry of Science and Technology of the People’s Republic of China.Google Scholar
  38. China Pharmaceutical Industry Investment Promotion Report. 2014. Invest in China of Ministry of Commerce of PRC. http://www.fdi.gov.cn. Accessed 8 Oct 2016.
  39. Coe, D. T., Helpman, E., & Hoffmaister, A. W. 1997. North-South R&D Spillovers. The Economic Journal, 107(440): 134–149.CrossRefGoogle Scholar
  40. Cook, T. D. & Campbell, D. T. (1979) Quasi-experimental design: Design and analysis issues for field settings. Skokie: Rand McNally.Google Scholar
  41. Cordell, A. 1973. Innovation, the multinational corporation: Some implications for national science policy. Long Range Planning, 6: 22–29.Google Scholar
  42. Creamer, D. 1976. Overseas research and development by United States multinationals, 1966–1975. New York: Conference Board.Google Scholar
  43. D’Agostino, L. M. 2015. The neglected effects of R&D captive offshoring in emerging countries on the creation of knowledge at home. Economia e Politica Industriale, 42(1): 61–91.CrossRefGoogle Scholar
  44. D’Agostino, L. M., & Santangelo, G. D. 2012. Do overseas R&D laboratories in emerging markets contribute to home knowledge creation? Management International Review, 52(2): 251–273.CrossRefGoogle Scholar
  45. Dhanaraj, C. (2016) Academy of International Business Conference call for paper: The locus of global innovation. https://aib.msu.edu/events/2016/callforpapers.asp], Accessed January 2, 2016.
  46. Dodgson, M. 2009. Asia’s national innovation systems: Institutional adaptability and rigidity in the face of global innovation challenges. Asia Pacific Journal of Management, 26(3): 589–609.CrossRefGoogle Scholar
  47. Doz, Y. 2011. Qualitative research for international business. Journal of International Business Studies, 42(5): 582–590.CrossRefGoogle Scholar
  48. Doz, Y. L., Santos, J., & Williamson, P. J. 2001. From global to metanational: How companies win in the knowledge economy. Boston: Harvard Business Press.CrossRefGoogle Scholar
  49. Dunning, J. H. 1958. American investment in British manufacturing industry. London: Allen and Unwin.Google Scholar
  50. Dunning, J. H. 1998. Location and the multinational enterprise: A neglected factor? Journal of International Business Studies, 29(1): 45–66.CrossRefGoogle Scholar
  51. Dunning, J. H. 2000. The eclectic paradigm as an envelope for economic and business theories of MNE activity. International Business Review, 9(2): 163–190.CrossRefGoogle Scholar
  52. Dunning, J. H., & Lundan, S. M. (2008). Multinational enterprises and the global economy. Cheltenham: Edward Elgar.Google Scholar
  53. Dunning, J. H., & Lundan, S. M. 2009. The internationalization of corporate R&D: A review of the evidence and some policy implications for home countries. Review of Policy Research, 26(1–2): 13–33.Google Scholar
  54. Dunning, J. H., & Narula, R. 2005. Multinationals and industrial competitiveness: A new agenda. Cheltenham: Edward Elgar.Google Scholar
  55. Edler, J. 2007. Internationalization of R&D empirical trends and challenges for policy and analysis. Paper presented at the Prime 3rd Annual Conference, Pisa, Italy.Google Scholar
  56. Fan, G., & Wang, X. 2001. NERI Index of Marketization of China by province. Beijing: Economic Science Press.Google Scholar
  57. Feinberg, S., & Gupta, K. 2004. Knowledge spillovers and the assignment of R&D responsibilities to foreign subsidiaries. Strategic Management Journal, 25(8/9): 823–845.CrossRefGoogle Scholar
  58. Fiercebiotech News. 2017. Riding on booming drug sales, AstraZeneca forms $133m China joint venture. Fiercebiotech News: November 27.Google Scholar
  59. Financial Times. 2015. AstraZeneca pours millions into China R&D. Financial Times.Google Scholar
  60. Fletcher, M., Zhao, Y., Plakoyiannaki, E., & Buck, T. 2018. Three pathways to case selection in international business: A twenty-year review, analysis and synthesis. International Business Review, 27(4): 755–766.Google Scholar
  61. Florida, R. 1997. The globalisation of R&D: Results of a survey of foreign-affiliated R&D laboratories in the USA. Research Policy, 26: 85–103.CrossRefGoogle Scholar
  62. Gibbert, M., & Ruigrok, W. 2010. The ‘what’ and ‘how’ of case study rigor: Three strategies based on published research. Organizational Research Methods, 13(4): 710–737.CrossRefGoogle Scholar
  63. Gill, M. J., Gill, D. J., & Roulet, T. J. 2018. Constructing trustworthy historical narratives: Criteria, principles and techniques. British Journal of Management, 29(1): 191–205.CrossRefGoogle Scholar
  64. Govindarajan, V., & Ramamurti, R. 2011. Reverse innovation, emerging markets, and global strategy. Global Strategy Journal, 1(3–4): 191–205.CrossRefGoogle Scholar
  65. Govindarajan, V., & Trimble, C. 2012. Reverse innovation: Create far from home, win everywhere. Boston:Harvard Business Press.CrossRefGoogle Scholar
  66. Greig, S. L. 2016. Osimertinib: First global approval. Drugs, 76(2): 263–273.CrossRefGoogle Scholar
  67. Griffith, R., Redding, S., & Van Reenen, J. 2004. Mapping the two faces of R&D: Productivity growth in a panel of OECD industries. Review of Economics and Statistics, 86(4): 883–895.CrossRefGoogle Scholar
  68. Guan, J. C., Yam, R., Tang, E., & Lau, A. 2009. Innovation strategy and performance during economic transition: Evidence in Beijing, China. Research Policy, 38(5): 802–812.CrossRefGoogle Scholar
  69. Gupta, A. K., & Govindarajan, V. 1991. Knowledge flow patterns, subsidiary strategic roles, and strategic control within MNCs. Academy of Management Proceedings, 1991(1): 21–25.CrossRefGoogle Scholar
  70. Håkanson, L. 1981. Organization and evolution of foreign R&D in Swedish multinationals. Human Geography, 63(1): 47–56.Google Scholar
  71. Haakonsson, S. J., & Ujjual, V. 2015. Internationalisation of R&D: New insights into multinational enterprises' R&D strategies in emerging markets. Management Revue, 26(2): 101–122.CrossRefGoogle Scholar
  72. Haour, G., & Jolly, D. 2014. China: The next innovation hot spot for the world. Journal of Business Strategy, 35(1): 2–8.CrossRefGoogle Scholar
  73. Heathcote, M. 1994. Challenging China. ICIS Chemical Business News: November 14.Google Scholar
  74. Hood, N., & Young, S. 1982. US multinational R&D: Corporate strategies and policy implications for the UK. Multinational Business, 2(1): 10–23.Google Scholar
  75. Ironwood Pharma News. 2018. Ironwood Pharmaceuticals provides fourth quarter and full year 2017 investor update. http://investor.ironwoodpharma.com/news-releases/news-release-details/ironwood-pharmaceuticalsprovides-fourth-quarter-and-full-year-2, Accessed February 15, 2018.
  76. Ito, B., & Wakasugi, R. 2007. What factors determine the mode of overseas R&D by multinationals? Empirical evidence. Research Policy, 36(8): 1275–1287.CrossRefGoogle Scholar
  77. Jain, S., Nair, A., & Ahlstrom, D. 2015. Introduction to the Special Issue: Towards a theoretical understanding of innovation and entrepreneurship in India. Asia Pacific Journal of Management, 32(4): 835–841.Google Scholar
  78. Jha, S., Dhanaraj, C., & Krishnan, R. 2015. How does multinational R&D evolve in emerging markets?. IMD working paper no. 2015–02, International Institute for Management Development.Google Scholar
  79. Jha, S., Dhanaraj, C., & Krishnan, R. 2018. From arbitrage to global innovation: Evolution of multinational R&D in emerging markets. Management International Review, 58(4): 633–661.Google Scholar
  80. Kuemmerle, W. 1997. Building effective R&D capabilities abroad. Harvard Business Review, 75: 61–72.Google Scholar
  81. Kuemmerle, W. 1999a. Foreign direct investment in industrial research in the pharmaceutical and electronics industries: Results from a survey of multinational firms. Research Policy, 28(1): 179–193.CrossRefGoogle Scholar
  82. Kuemmerle, W. 1999b. The drivers of foreign direct investment into research and development: An empirical investigation. Journal of International Business Studies, 30(1): 1–24.CrossRefGoogle Scholar
  83. Kumaraswamy, A., Mudambi, R., Saranga, H., & Tripathy, A. 2012. Catch-up strategies in the Indian auto components industry: Domestic firms’ responses to market liberalization. Journal of International Business Studies, 43(4): 368–395.CrossRefGoogle Scholar
  84. Lema, R., Quadros, R., & Schmitz, H. 2015. Reorganising global value chains and building innovation capabilities in Brazil and India. Research Policy, 44(7): 1376–1386.CrossRefGoogle Scholar
  85. Li, X. 2009. China’s regional innovation capacity in transition: An empirical approach. Research Policy, 38(2): 338–357.CrossRefGoogle Scholar
  86. Liu, M., & Chen, S. 2012. MNCs’ offshore R&D networks in host country's regional innovation system: The case of Taiwan-based firms in China. Research Policy, 41(6): 1107–1120.CrossRefGoogle Scholar
  87. Liu, F. C., Simon, D. F., Sun, Y. T., & Cao, C. 2011. China's innovation policies: Evolution, institutional structure, and trajectory. Research Policy, 40(7): 917–931.CrossRefGoogle Scholar
  88. Lu, Y., Tsang, E. W., & Peng, M. W. 2008. Knowledge management and innovation strategy in the Asia Pacific: Toward an institution-based view. Asia Pacific Journal of Management, 25(3): 361–374.CrossRefGoogle Scholar
  89. Lundvall, B.-Å. 1992. National systems of innovation: An analytical framework. London: Pinter.Google Scholar
  90. Lundvall, B.-Å. 2007. National innovation systems—Analytical concept and development tool. Industry and Innovation, 14(1): 95–119.CrossRefGoogle Scholar
  91. Mabey, C., & Zhao, S. 2017. Managing five paradoxes of knowledge exchange in networked organizations: New priorities for HRM? Human Resource Management Journal, 27(1): 39–57.CrossRefGoogle Scholar
  92. Manea, J., & Pearce, R. 2004. Multinationals and transition: Business strategies, technology and transformation in Central and Eastern Europe. Basingstoke: Palgrave-Macmillan.CrossRefGoogle Scholar
  93. McKinsey 2012. Pharmaceutical innovation: AstraZeneca’s experience in China. McKinsey Quarterly, 1: 93–95.Google Scholar
  94. Meyer, K. E., Mudambi, R., & Narula, R. 2011. Multinational enterprises and local contexts: The opportunities and challenges of multiple embeddedness. Journal of Management Studies, 48: 235–252.Google Scholar
  95. Ministry of Commerce, PRC. 2005. China investment guide: Sweden, invest in China serials, Investment Promotion Agency of Ministry of Commerce Publication. Beijing: Ministry of Commerce, PRC.Google Scholar
  96. Ministry of Commerce, PRC. 2006. I am Jiangsu, invest in China serials, Investment Promotion Agency of Ministry of Commerce Publication. Beijing: Ministry of Commerce, PRC.Google Scholar
  97. Mudambi, R., Piscitello, L., & Rabbiosi, L. 2014. Reverse knowledge transfer in MNEs: Subsidiary innovativeness and entry modes. Long Range Planning, 47(1): 49–63.CrossRefGoogle Scholar
  98. Mudambi, R., & Santangelo, G. D. 2016. From shallow resource pools to emerging clusters: The role of multinational enterprise subsidiaries in peripheral areas. Regional Studies, 50(12): 1965–1979.Google Scholar
  99. Nair, A., Guldiken, O., Fainshmidt, S., & Pezeshkan, A. 2015. Innovation in India: A review of past research and future directions. Asia Pacific Journal of Management, 32(4): 925–958.CrossRefGoogle Scholar
  100. Niosi, J. 1999. The internationalization of industrial R&D from technology transfer to the learning organization. Research Policy, 28(2–3): 107–117.Google Scholar
  101. Pearce, R., & Papanastassiou, M. 1997. Global innovation strategies of MNEs and European integration: The role of regional R&D facilities. In R. Pearce (Ed.). Global competition and technology: 123–152. New York: St. Martin’s.Google Scholar
  102. Pearce, R. D., & Papanastassiou, M. 1999. Overseas R&D and the strategic evolution of MNEs: Evidence from laboratories in the UK. Research Policy, 28(1): 23–41.CrossRefGoogle Scholar
  103. Pearce, R., & Papanastassiou, M. 2006. Multinationals and national systems of innovation: Strategy and policy issues. In A. T. Tavares & A. Teixeira (Eds.), Multinationals, clusters and innovation: Does public policy matter? Basingstoke: Palgrave Macmillan.Google Scholar
  104. Pederson, J. P. 2008. International directory of company histories. Chicago: St. James.Google Scholar
  105. Prabhu, J., & Jain, S. 2015. Innovation and entrepreneurship in India: Understanding jugaad. Asia Pacific Journal of Management, 32(4): 843–868.CrossRefGoogle Scholar
  106. Prashantham, S., & Dhanaraj, C. 2015. MNE ties and new venture internationalization: Exploratory insights from India. Asia Pacific Journal of Management, 32(4): 901–924.CrossRefGoogle Scholar
  107. PriceWaterhouseCoopers. 2015. Global innovation 1,000: Innovation’s new world order. PriceWaterhouseCooper PLC.Google Scholar
  108. Reddy, P. 1997. New trends in globalization of corporate R&D and implications for innovation capability in host countries: A survey from India. World Development, 25(11): 1821–1837.CrossRefGoogle Scholar
  109. Reuters, T. 2010. AstraZeneca CEO sees China growth doubling. Reuters: June 26.Google Scholar
  110. Reuters, T. 2017. AstraZeneca, Chi-Med take kidney cancer drug into final testing. Reuters: June 29.Google Scholar
  111. Rodrigues, S. B., & Child, J. 2008. Corporate Co-Evolution: A Political Perspective, Vol 4. Chichester: John Wiley & Sons.CrossRefGoogle Scholar
  112. Ronstadt, R. C. 1978. International R&D: The establishment and evolution of research and development abroad by seven US multinationals. Journal of International Business Studies, 9(1): 7–24.CrossRefGoogle Scholar
  113. Safarian, A. E. 1966. Foreign ownership of Canadian industry. Toronto: McGraw-Hill.Google Scholar
  114. Schmiele, A., & Mangelsdorf, A. 2009. Drivers of international R&D to Asian economies: A perspective from German companies. Paper presented at the 6th Asialics International Conference on “Linkages in Innovation Systems: Global and Local Perspectives,” Hong Kong University of Science and Technology, Hong Kong.Google Scholar
  115. Shin, K., Kim, S. J., & Park, G. 2016. How does the partner type in R&D alliances impact technological innovation performance? A study on the Korean biotechnology industry. Asia Pacific Journal of Management, 33(1): 141–164.CrossRefGoogle Scholar
  116. Siggelkow, N. 2007. Persuasion with case studies. Academy of Management Journal, 50(1): 20–24.CrossRefGoogle Scholar
  117. SIPO. 2015. Patent database. Beijing: State Intellectual Property Office, China.Google Scholar
  118. Song, J., & Shin, J. 2008. The paradox of technological capabilities: A study of knowledge sourcing from host countries of overseas R&D operations. Journal of International Business Studies, 39(2): 291–303.CrossRefGoogle Scholar
  119. Song, J., Asakawa, K., & Chu, Y. 2011. What determines knowledge sourcing from host locations of overseas R&D operations?: A study of global R&D activities of Japanese multinationals. Research Policy, 40(3): 380–390.CrossRefGoogle Scholar
  120. Tan, X., Liu, X., & Shao, H. 2017. Healthy China 2030: A vision for health care. Value in Health Regional Issues, 12: 112–114.CrossRefGoogle Scholar
  121. The Independent. 1998. Has Zeneca chosen wisely?. The Independent: December 11.Google Scholar
  122. Turnheim, B., & Geels, F. W. 2012. Regime destabilisation as the flipside of energy transitions: Lessons from the history of the British coal industry (1913–1997). Energy Policy, 50: 35–49.CrossRefGoogle Scholar
  123. Turnheim, B., & Geels, F. W. 2013. The destabilisation of existing regimes: Confronting a multi-dimensional framework with a case study of the British coal industry (1913–1967). Research Policy, 42(10): 1749–1767.CrossRefGoogle Scholar
  124. UNCTAD. 2005. World investment report: Transnational corporations and the internationalisation of R&D. New York and Geneva: United Nations.Google Scholar
  125. UNCTAD. 2012. Technology and innovation report. New York and Geneva: United Nations.Google Scholar
  126. UNCTAD. 2016. Investor nationality: Policy challenges. New York and Geneva: United Nations.Google Scholar
  127. Verbeke, A., & Kano, L. 2015. The new internalization theory and multinational enterprises from emerging economies: A business history perspective. Business History Review, 89(03): 415–445.CrossRefGoogle Scholar
  128. Vernon, R. 1966. International investment and international trade in the product cycle. Quarterly Journal of Economics, 80(2): 190–207.CrossRefGoogle Scholar
  129. von Zedtwitz, M., & Gassmann, O. 2002. Market versus technology drive in R&D internationalization: Four different patterns of managing research and development. Research Policy, 31(4): 569–588.CrossRefGoogle Scholar
  130. von Zedtwitz, M., Corsi, S., Søberg, P. V., & Frega, R. 2015. A typology of reverse innovation. Journal of Product Innovation Management, 32(1): 12–28.Google Scholar
  131. Wall Street Journal. 2001a. AstraZeneca, Shanghai University undertake study of schizophrenia. Wall Street Journal: April 11.Google Scholar
  132. Wall Street Journal. 2001b. AstraZeneca invests $100 million in China plant, its biggest in Asia. Wall Street Journal: April 29.Google Scholar
  133. Wang, C., Hong, J., Kafouros, M., & Wright, M. 2012. Exploring the role of government involvement in outward FDI from emerging economies. Journal of International Business Studies, 43(7): 655–676.CrossRefGoogle Scholar
  134. Washington Business Journal. 2017. MedImmune gets OK from China to pursue arthritis drug in joint venture deal. Washington Business Journal: January 19.Google Scholar
  135. Welch, C., & Piekkari, R. 2017. How should we (not) judge the ‘quality’of qualitative research? A re-assessment of current evaluative criteria in international business. Journal of World Business, 52(5): 714–725.CrossRefGoogle Scholar
  136. Welch, C., Piekkari, R., Plakoyiannaki, E., & Paavilainen-Mäntymäki, E. 2011. Theorising from case studies: Towards a pluralist future for international business research. Journal of International Business Studies, 42(5): 740–762.CrossRefGoogle Scholar
  137. World Scientific. 2003. The Asia-Pacific biotech directory. Hackensack: World Scientific.Google Scholar
  138. Yang, Q., & Jiang, C. X. 2007. Location advantages and subsidiaries’ R&D activities in emerging economies: Exploring the effect of employee mobility. Asia Pacific Journal of Management, 24(3): 341–358.CrossRefGoogle Scholar
  139. Yin, R. K. 2014. Case study research: Design and methods, 5th ed. Thousand Oaks: Sage.Google Scholar
  140. Yu, S. 2011. Information technology in multinational corporations: The managerial role of enterprise resource planning system in headquarters-subsidiary power tussle and local performance. Saarbrücken: Lambert Academic.Google Scholar
  141. Zander, I. 1999. How do you mean ‘global’? An empirical investigation of innovation networks in the multinational corporation. Research Policy, 28(2/3): 195–213.CrossRefGoogle Scholar
  142. Zeneca Group PLC. 1994. Annual report. London: Zeneca Group PLC.Google Scholar
  143. Zhang, S., & Pearce, R. D. 2011. Multinationals in China: Business strategy, technology and economic development. Basingstoke: Palgrave Macmillan.Google Scholar
  144. Zhang, S., Zhao, S., Bournakis, I., Pearce, R.D., & Papanastassiou, M. 2018. Subsidiary roles as determinants of subsidiary technology sourcing: Empirical evidence from China. Economia Politica, 35(2): 623–648.Google Scholar
  145. Zhou, C., Wang, M., Cheng, Y., Chen, Y., Zhao, Y., Shi, Y. K., & Wu, Y. L. 2017. 1354POsimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced NSCLC: Updated phase II study results including progression-free survival (PFS). Annals of Oncology, 28(S5): Sept. 1.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Management, Leadership and Organization, Business SchoolMiddlesex UniversityLondonUK
  2. 2.School of Management, Royal HollowayUniversity of LondonSurreyUK
  3. 3.Hubei University of EconomicsWuhanChina
  4. 4.Tilburg UniversityTilburgThe Netherlands

Personalised recommendations